Logo image of PYPD

POLYPID LTD (PYPD) Stock Fundamental Analysis

NASDAQ:PYPD - Nasdaq - IL0011326795 - Common Stock - Currency: USD

3.74  +0.16 (+4.47%)

After market: 3.6 -0.14 (-3.74%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to PYPD. PYPD was compared to 195 industry peers in the Pharmaceuticals industry. PYPD may be in some trouble as it scores bad on both profitability and health. PYPD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PYPD has reported negative net income.
PYPD had a negative operating cash flow in the past year.
PYPD had negative earnings in each of the past 5 years.
PYPD had a negative operating cash flow in each of the past 5 years.
PYPD Yearly Net Income VS EBIT VS OCF VS FCFPYPD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

With a Return On Assets value of -115.07%, PYPD is not doing good in the industry: 77.44% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -377.67%, PYPD is doing worse than 76.92% of the companies in the same industry.
Industry RankSector Rank
ROA -115.07%
ROE -377.67%
ROIC N/A
ROA(3y)-141.15%
ROA(5y)-114.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PYPD Yearly ROA, ROE, ROICPYPD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PYPD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYPD Yearly Profit, Operating, Gross MarginsPYPD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for PYPD has been increased compared to 1 year ago.
The number of shares outstanding for PYPD has been increased compared to 5 years ago.
The debt/assets ratio for PYPD has been reduced compared to a year ago.
PYPD Yearly Shares OutstandingPYPD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PYPD Yearly Total Debt VS Total AssetsPYPD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -17.07, we must say that PYPD is in the distress zone and has some risk of bankruptcy.
PYPD's Altman-Z score of -17.07 is on the low side compared to the rest of the industry. PYPD is outperformed by 78.46% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that PYPD is not too dependend on debt financing.
PYPD has a Debt to Equity ratio of 0.08. This is comparable to the rest of the industry: PYPD outperforms 50.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -17.07
ROIC/WACCN/A
WACCN/A
PYPD Yearly LT Debt VS Equity VS FCFPYPD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

PYPD has a Current Ratio of 1.31. This is a normal value and indicates that PYPD is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of PYPD (1.31) is worse than 75.90% of its industry peers.
A Quick Ratio of 1.31 indicates that PYPD should not have too much problems paying its short term obligations.
PYPD's Quick ratio of 1.31 is on the low side compared to the rest of the industry. PYPD is outperformed by 67.18% of its industry peers.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.31
PYPD Yearly Current Assets VS Current LiabilitesPYPD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.30% over the past year.
EPS 1Y (TTM)66.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PYPD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.89% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.38%
EPS Next 2Y32.86%
EPS Next 3Y23.37%
EPS Next 5Y17.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PYPD Yearly Revenue VS EstimatesPYPD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M 150M 200M
PYPD Yearly EPS VS EstimatesPYPD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PYPD. In the last year negative earnings were reported.
Also next year PYPD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYPD Price Earnings VS Forward Price EarningsPYPD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYPD Per share dataPYPD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as PYPD's earnings are expected to grow with 23.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.86%
EPS Next 3Y23.37%

More info and screens

0

5. Dividend

5.1 Amount

PYPD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POLYPID LTD

NASDAQ:PYPD (6/25/2025, 8:04:00 PM)

After market: 3.6 -0.14 (-3.74%)

3.74

+0.16 (+4.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners44.5%
Inst Owner Change-95.08%
Ins Owners9.02%
Ins Owner ChangeN/A
Market Cap38.11M
Analysts82.22
Price Target13.01 (247.86%)
Short Float %0.49%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.66%
Min EPS beat(2)-21.92%
Max EPS beat(2)-19.4%
EPS beat(4)2
Avg EPS beat(4)-7.69%
Min EPS beat(4)-21.92%
Max EPS beat(4)5.63%
EPS beat(8)4
Avg EPS beat(8)4.15%
EPS beat(12)8
Avg EPS beat(12)6.4%
EPS beat(16)10
Avg EPS beat(16)4.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)15.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.13%
EPS NY rev (1m)-3.7%
EPS NY rev (3m)13.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.96
P/tB 4.96
EV/EBITDA N/A
EPS(TTM)-4.26
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-2.16
FCFYN/A
OCF(TTM)-2.16
OCFYN/A
SpS0
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.07%
ROE -377.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.15%
ROA(5y)-114.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.69%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.31
Altman-Z -17.07
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.45%
Cap/Depr(5y)86.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.91%
EPS Next Y60.38%
EPS Next 2Y32.86%
EPS Next 3Y23.37%
EPS Next 5Y17.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.43%
OCF growth 3YN/A
OCF growth 5YN/A